Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma

Authors
Publication date
1 January 2015
Publisher
'American Society of Clinical Oncology (ASCO)'

Abstract

1 page(s

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Macquarie University ResearchOnline

    redirect
    Last time updated on 25/04/2017